In This Issue
Cancer Discov December 1 2016 6 (12) 1293-1295; DOI:10.1158/2159-8290.CD-ITI6-12
A patient with NSCLC responded to a type II MET inhibitor in combination with an EGFR TKI after acquisition of a METD1228V mutation conferred resistance to a type I MET inhibitor.
Multisite sequencing of high-grade serous ovarian cancers highlights genomic instability as an early event in disease progression and identifies a subset of serous tubal intraepithelial carcinomas as metastases rather than precursor lesions.
Vemurafenib plus irinotecan and cetuximab was generally well tolerated and achieved a 35% response rate in patients with BRAFV600E metastatic colorectal cancer, and responses correlated with BRAFV600E cfDNA levels.
TGFβ1 promotes a SMAD3-dependent increase in PD-1 expression on TILs, suppressing antitumor immunity and increasing tumor growth in vivo.
Neoadjuvant immunotherapy extends survival and reduces metastatic disease more effectively than adjuvant immunotherapy in mouse models of metastatic triple-negative breast cancer.